The lawsuit, filed in the United States District Court for the District of New Jersey, centers on a period between November 25, 2025, and May 4, 2026. Plaintiffs allege that Embecta executives repeatedly reaffirmed revenue guidance of up to $1.093 billion, even as the company faced significant attrition in its U.S. pen needle business and weakening retail demand. The discrepancy culminated on May 5, 2026, when the stock price plunged from $9.25 to $3.90, alongside a drastic dividend cut from $0.15 to $0.01 per share.

For institutional holders and pension funds, the litigation presents a fiduciary challenge. Legal counsel at Levi & Korsinsky, LLP, which is spearheading the effort, argues that the magnitude of the guidance revision—which saw adjusted EPS projections slashed by roughly 40%—warrants active oversight. Appointing a lead plaintiff allows large holders to influence litigation strategy and settlement negotiations under the Private Securities Litigation Reform Act. Participation in the action requires no upfront fees, as the case operates on a contingency basis, but fiduciaries must weigh the necessity of maximizing portfolio recovery against their internal governance obligations.